The case for & against
Bull & Bear analysis
Bullish
InterCure Ltd. (NASDAQ: INCR) is a prominent player in the medical cannabis industry, primarily based in Israel. With a focus on producing and distributing pharmaceutical-grade cannabis products, the company has established a strongmarket presence, having approximately 30% of the Israeli medical cannabis market share. InterCure’s vertically integrated model facilitates operational efficiencies and positions it favorably for expansion opportunities both locally and internationally, especially amidst evolving regulations that could further open up markets for cannabis products.
Bull says
- ↑Revenue reached $150M in 2022, up 77% YoY, signaling rapid growth momentum.
- ↑Adjusted EBITDA of $32M (22% of revenue) and 41% gross margin show strong profitability.
- ↑Vertically integrated operations reduce costs and improve supply control across cultivation and distribution.
- ↑Prescription reform projected to increase Israeli medical cannabis demand to 85t by 2023.
- ↑Betel acquisition bolsters market share; 2,500 new patients enrolled in July alone.
- ↑Cash position of $96M and 18% YoY patient growth support expansion plans.
Bear says
- ↓Negative earnings outlook and downward revisions signal potential disappointment in future profits.
- ↓Aggressive pricing by competitors may compress InterCure’s margins and hurt profitability.
- ↓New import restrictions risk supply shortages and may disrupt product availability in Israel.
- ↓High short interest indicates market skepticism over the company’s growth trajectory.
- ↓Thin trading liquidity could hamper stock stability and deter institutional investors.
- ↓Tight regulations and dependency on external supply chains pose execution risks.
Earnings Call · Q3 2021 · Mgmt. Guidance
Updated 06-29-2026bullish
Transcript signals
Bull points
- during the month of October, the company reached a record of one ton of medical cannabis products dispensed in one month. This represents our leading position with approximately 30% market share of the Israeli medical cannabis.
- we have increased our revenues from $3 million to a run rate of over $100 million, 33 times higher and keep growing.
- InterQ reported revenue of $25 million or 62 million new Israeli shekels for the third quarter of 2021, three times greater than the third quarter of 2020 and up 36% sequentially. This also represents the company's seventh consecutive quarter of high-digit growth and its fifth consecutive quarter with positive cash flow from operation.
Read full transcript analysis ›